1. Home
  2. EMX vs ALT Comparison

EMX vs ALT Comparison

Compare EMX & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EMX
  • ALT
  • Stock Information
  • Founded
  • EMX N/A
  • ALT 1997
  • Country
  • EMX Canada
  • ALT United States
  • Employees
  • EMX N/A
  • ALT N/A
  • Industry
  • EMX
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • EMX
  • ALT Health Care
  • Exchange
  • EMX Nasdaq
  • ALT Nasdaq
  • Market Cap
  • EMX 338.0M
  • ALT 292.0M
  • IPO Year
  • EMX N/A
  • ALT N/A
  • Fundamental
  • Price
  • EMX $3.65
  • ALT $3.83
  • Analyst Decision
  • EMX Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • EMX 2
  • ALT 6
  • Target Price
  • EMX $5.38
  • ALT $17.40
  • AVG Volume (30 Days)
  • EMX 431.3K
  • ALT 3.0M
  • Earning Date
  • EMX 08-11-2025
  • ALT 08-12-2025
  • Dividend Yield
  • EMX N/A
  • ALT N/A
  • EPS Growth
  • EMX N/A
  • ALT N/A
  • EPS
  • EMX 0.04
  • ALT N/A
  • Revenue
  • EMX $29,864,000.00
  • ALT $20,000.00
  • Revenue This Year
  • EMX $11.08
  • ALT N/A
  • Revenue Next Year
  • EMX $3.72
  • ALT $761,880.20
  • P/E Ratio
  • EMX $79.37
  • ALT N/A
  • Revenue Growth
  • EMX N/A
  • ALT N/A
  • 52 Week Low
  • EMX $1.59
  • ALT $2.90
  • 52 Week High
  • EMX $3.66
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • EMX 74.62
  • ALT 51.79
  • Support Level
  • EMX $3.04
  • ALT $3.35
  • Resistance Level
  • EMX $3.37
  • ALT $3.66
  • Average True Range (ATR)
  • EMX 0.12
  • ALT 0.19
  • MACD
  • EMX 0.03
  • ALT 0.07
  • Stochastic Oscillator
  • EMX 97.58
  • ALT 86.18

About EMX EMX Royalty Corporation (Canada)

EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: